NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Adenocarcinoma



Study findings from University of Texas broaden understanding of adenocarcinoma



September 2nd, 2008

According to recent research from the United States, " We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma. Patients and Methods Chemotherapy consisted of gemcitabine (750 mg/m(2)) and cisplatin (30 mg/m(2)) given every 2 weeks for four doses."

"Chemoradiation consisted of four weekly infusions of gemcitabine (400 mg/m(2)) combined with radiation therapy (30 Gy in 10 fractions administered over 2 weeks) delivered 5 days per week. Patients underwent restaging 4 to 6 weeks after completion of chemoradiation...


Source: Cancer Weekly (2008-09-02)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login